Towards precision medicine: The application of omics technologies in asthma management [version 2; referees: 2 approved]

Chiara Scelfo, Carla Galeone, Francesca Bertolini, Marco Caminati, Patrizia Ruggiero, Nicola Facciolongo, Francesco Menzella

Research output: Contribution to journalArticle

Abstract

Asthma is a chronic obstructive respiratory disease characterised by bronchial inflammation. Its biological and clinical features have been widely explored and a number of pharmacological treatments are currently available. Currently several aspects of asthma pathophysiological background remain unclear, and this is represent a limitation for the traditional asthma phenotype approach. In this scenario, the identification of new molecular and clinical biomarkers may be helpful in order to better understand the disease, define specific diagnostic tools and highlight relevant novel targets for pharmacological treatments. Omics technologies offer innovative research tools for addressing the above mentioned goals. However, there is still a lot to do both in the fields of basic research and in the clinical application. Recently, genome-wide association studies, microRNAs and proteomics are contributing to enrich the available data for the identification of new asthma biomarkers. A precise approach to the patient with asthma, particularly with severe uncontrolled asthma, requires new and specific therapeutic targets, but also proper tools able to drive the clinician in tailoring the treatment. On the other hand, there is a need of predictors to treatment's response, particularly in the field of biological drugs, whose sustainability implies a correct and precise selection of the patients. Translating acquired omics knowledge in clinical practice may address the unmet needs described above, but large-scale studies are required in order to confirm their relevance and effectiveness in daily practice. Thus in our opinion the application of omics is still lagging in the real-life setting.

Original languageEnglish
Article number423
JournalF1000Research
Volume7
DOIs
Publication statusPublished - Jan 1 2018

Fingerprint

Precision Medicine
Medicine
Asthma
Biomarkers
Technology
Pulmonary diseases
MicroRNAs
Sustainable development
Genes
Bronchial Diseases
Association reactions
Pharmacology
Therapeutics
Genome-Wide Association Study
Research
Pharmaceutical Preparations
Proteomics
Patient Selection
Inflammation
Phenotype

Keywords

  • Inflammation
  • Omics sciences
  • Precision medicine
  • Severe asthma

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Microbiology(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Scelfo, C., Galeone, C., Bertolini, F., Caminati, M., Ruggiero, P., Facciolongo, N., & Menzella, F. (2018). Towards precision medicine: The application of omics technologies in asthma management [version 2; referees: 2 approved]. F1000Research, 7, [423]. https://doi.org/10.12688/f1000research.14309.2

Towards precision medicine : The application of omics technologies in asthma management [version 2; referees: 2 approved]. / Scelfo, Chiara; Galeone, Carla; Bertolini, Francesca; Caminati, Marco; Ruggiero, Patrizia; Facciolongo, Nicola; Menzella, Francesco.

In: F1000Research, Vol. 7, 423, 01.01.2018.

Research output: Contribution to journalArticle

Scelfo, Chiara ; Galeone, Carla ; Bertolini, Francesca ; Caminati, Marco ; Ruggiero, Patrizia ; Facciolongo, Nicola ; Menzella, Francesco. / Towards precision medicine : The application of omics technologies in asthma management [version 2; referees: 2 approved]. In: F1000Research. 2018 ; Vol. 7.
@article{52df9378b8194b37984ec5eeac7e720c,
title = "Towards precision medicine: The application of omics technologies in asthma management [version 2; referees: 2 approved]",
abstract = "Asthma is a chronic obstructive respiratory disease characterised by bronchial inflammation. Its biological and clinical features have been widely explored and a number of pharmacological treatments are currently available. Currently several aspects of asthma pathophysiological background remain unclear, and this is represent a limitation for the traditional asthma phenotype approach. In this scenario, the identification of new molecular and clinical biomarkers may be helpful in order to better understand the disease, define specific diagnostic tools and highlight relevant novel targets for pharmacological treatments. Omics technologies offer innovative research tools for addressing the above mentioned goals. However, there is still a lot to do both in the fields of basic research and in the clinical application. Recently, genome-wide association studies, microRNAs and proteomics are contributing to enrich the available data for the identification of new asthma biomarkers. A precise approach to the patient with asthma, particularly with severe uncontrolled asthma, requires new and specific therapeutic targets, but also proper tools able to drive the clinician in tailoring the treatment. On the other hand, there is a need of predictors to treatment's response, particularly in the field of biological drugs, whose sustainability implies a correct and precise selection of the patients. Translating acquired omics knowledge in clinical practice may address the unmet needs described above, but large-scale studies are required in order to confirm their relevance and effectiveness in daily practice. Thus in our opinion the application of omics is still lagging in the real-life setting.",
keywords = "Inflammation, Omics sciences, Precision medicine, Severe asthma",
author = "Chiara Scelfo and Carla Galeone and Francesca Bertolini and Marco Caminati and Patrizia Ruggiero and Nicola Facciolongo and Francesco Menzella",
year = "2018",
month = "1",
day = "1",
doi = "10.12688/f1000research.14309.2",
language = "English",
volume = "7",
journal = "F1000Research",
issn = "2046-1402",
publisher = "F1000 Research Ltd.",

}

TY - JOUR

T1 - Towards precision medicine

T2 - The application of omics technologies in asthma management [version 2; referees: 2 approved]

AU - Scelfo, Chiara

AU - Galeone, Carla

AU - Bertolini, Francesca

AU - Caminati, Marco

AU - Ruggiero, Patrizia

AU - Facciolongo, Nicola

AU - Menzella, Francesco

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Asthma is a chronic obstructive respiratory disease characterised by bronchial inflammation. Its biological and clinical features have been widely explored and a number of pharmacological treatments are currently available. Currently several aspects of asthma pathophysiological background remain unclear, and this is represent a limitation for the traditional asthma phenotype approach. In this scenario, the identification of new molecular and clinical biomarkers may be helpful in order to better understand the disease, define specific diagnostic tools and highlight relevant novel targets for pharmacological treatments. Omics technologies offer innovative research tools for addressing the above mentioned goals. However, there is still a lot to do both in the fields of basic research and in the clinical application. Recently, genome-wide association studies, microRNAs and proteomics are contributing to enrich the available data for the identification of new asthma biomarkers. A precise approach to the patient with asthma, particularly with severe uncontrolled asthma, requires new and specific therapeutic targets, but also proper tools able to drive the clinician in tailoring the treatment. On the other hand, there is a need of predictors to treatment's response, particularly in the field of biological drugs, whose sustainability implies a correct and precise selection of the patients. Translating acquired omics knowledge in clinical practice may address the unmet needs described above, but large-scale studies are required in order to confirm their relevance and effectiveness in daily practice. Thus in our opinion the application of omics is still lagging in the real-life setting.

AB - Asthma is a chronic obstructive respiratory disease characterised by bronchial inflammation. Its biological and clinical features have been widely explored and a number of pharmacological treatments are currently available. Currently several aspects of asthma pathophysiological background remain unclear, and this is represent a limitation for the traditional asthma phenotype approach. In this scenario, the identification of new molecular and clinical biomarkers may be helpful in order to better understand the disease, define specific diagnostic tools and highlight relevant novel targets for pharmacological treatments. Omics technologies offer innovative research tools for addressing the above mentioned goals. However, there is still a lot to do both in the fields of basic research and in the clinical application. Recently, genome-wide association studies, microRNAs and proteomics are contributing to enrich the available data for the identification of new asthma biomarkers. A precise approach to the patient with asthma, particularly with severe uncontrolled asthma, requires new and specific therapeutic targets, but also proper tools able to drive the clinician in tailoring the treatment. On the other hand, there is a need of predictors to treatment's response, particularly in the field of biological drugs, whose sustainability implies a correct and precise selection of the patients. Translating acquired omics knowledge in clinical practice may address the unmet needs described above, but large-scale studies are required in order to confirm their relevance and effectiveness in daily practice. Thus in our opinion the application of omics is still lagging in the real-life setting.

KW - Inflammation

KW - Omics sciences

KW - Precision medicine

KW - Severe asthma

UR - http://www.scopus.com/inward/record.url?scp=85047466006&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047466006&partnerID=8YFLogxK

U2 - 10.12688/f1000research.14309.2

DO - 10.12688/f1000research.14309.2

M3 - Article

AN - SCOPUS:85047466006

VL - 7

JO - F1000Research

JF - F1000Research

SN - 2046-1402

M1 - 423

ER -